Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel
OTCMKTS:ISCO

International Stem Cell Q2 2025 Earnings Results & Report

International Stem Cell logo
$0.16 -0.01 (-7.46%)
As of 11/13/2026 09:38 AM Eastern

International Stem Cell reported Q2 2025 earnings on August 14, 2025. The company reported EPS of $0.01, while revenue was $2.45 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

International Stem Cell EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

International Stem Cell Revenue Results

Actual Revenue
$2.45 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

International Stem Cell Q2 2025 Earnings FAQ

International Stem Cell (OTCMKTS:ISCO) reported earnings of $0.01 per share for Q2 2025. The report was announced on Thursday, August 14, 2025.

International Stem Cell reported revenue of $2.45 million for Q2 2025.

International Stem Cell Earnings Headlines

International Stem Cell (ISCO) Hisse Fiyatı Bugün Ne Kadar?
October 13, 2026  |  tr.investing.comhttps://tr.investing.com/equities/intl-stem-cell-corp
ISCO - International Stem Cell Corporation
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/ISCO
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
November 15 at 1:00 AM  |  Digest Publishing (Ad)
Der aktuelle Kurs der International Stem Cell Corp Aktie beträgt 0,490.
August 27, 2026  |  de.investing.comhttps://de.investing.com/equities/intl-stem-cell-corp
ما هو سعر سهم International Stem Cell (ISCO) اليوم؟
August 22, 2026  |  sa.investing.comhttps://sa.investing.com/equities/intl-stem-cell-corp
Spaceflight accelerates the aging of human blood-forming stem cells
September 9, 2025  |  yahoo.comhttps://www.yahoo.com/news/articles/spaceflight-accelerates-aging-human-blood-183342425.html
See More International Stem Cell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like International Stem Cell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on International Stem Cell and other key companies, straight to your email.

About International Stem Cell

International Stem Cell (OTCMKTS:ISCO) Corporation (OTCMKTS:ISCO) is a biotechnology company focused on developing regenerative medicine products based on human parthenogenetic stem cells. These cells are derived from unfertilized human oocytes and are intended to provide an alternative source of pluripotent stem cells without using fertilized embryos.

The company has researched potential applications for its stem-cell technology in areas including ophthalmology, neurological disorders and tissue regeneration. Its development programs have included stem-cell-derived retinal pigment epithelial cells for eye diseases and other preclinical therapeutic applications. The company has also been associated with Lifeline Skin Care, a business offering skincare products formulated with human stem-cell-derived growth factors and related biotechnology ingredients.

International Stem Cell Corporation was established in the United States and has historically conducted research and commercial activities through subsidiaries and partners. Public information about the company’s current operations, leadership and geographic reach is limited, and its development programs and business activities may have changed over time.

View International Stem Cell Profile
Earnings Tools